Skip to content

Fecal microbiota transplant capsules as a treatment in patients with ulcerative colitis

Efficacy and Safety Of Oral Lyophilized Fecal Microbiome Capsules For Induction And Maintenance Of Remission In Moderately Severe Ulcerative Colitis - FLORAL-UC

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/01/062063
Enrollment
100
Registered
2024-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K51- Ulcerative colitis

Interventions

Intervention1: FMT capsule: Patients with moderately active ulcerative colitis will receive FMT capsules in addition to the standard of care for induction and maintenance of remission. The duration o

Sponsors

Vardhman Textiles Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of UC with active disease, defined as a total Mayo score of 6â??9, and a Mayo endoscopic subscore of 1 or more. 2. Any disease extent : E1, E2 or E3 3. Diagnosis (endoscopic or radiographic and histological) of UC at least 6 months prior to enrolment into the study 4. Subjects who are willing and able to comply with treatment plan, laboratory tests. 5. Subjects who are willing to provide a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Subjects without previous treatment for IBD (i.e. treatment-naïve). 2. Active or latent or inadequately treated infections(includingClostridiodes difficile, Cytomegalovirus, Mycobacterium tuberculosis, etc.) 3. Subjects displaying clinical signs of fulminant colitis or toxic megacolon. 4. Subjects infected with human immunodeficiency virus (HIV) or hepatitis B or C viruses. 5. Subjects with current malignancies or a past history of malignancies. 6. Subjects with current or recent history of severe, progressive, or uncontrolled renal, hepatic, haematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological disease. 7. Pregnant females.

Design outcomes

Primary

MeasureTime frame
Clinical remission (defined as total Mayo score â?¤2, with no individual sub-score exceeding 1 point)Timepoint: Week 8, Week 48

Secondary

MeasureTime frame
Clinical response (defined as decrease in total Mayo score by at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding sub-score of at least 1 point or absolute rectal bleeding sub-score of 0 or 1)Timepoint: Week 8, Week 48;Endoscopic remission (defined as endoscopic Mayo sub-score of 0)Timepoint: Week 8, Week 48

Countries

India

Contacts

Public ContactAjit Sood

Dayanand Medical College and Hospital, Ludhiana

ajitsood10@gmail.com9815400718

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 9, 2026